cAMPfield Strengthens Leadership Team with Key Executive Appointments, Including Graham Heap, MD, PhD as President, R&D, to Advance Prifemilast into Global Phase 2 Development for Inflammatory Bowel Disease

PrifemilastPositive

AI Analysis

Summary

cAMPfield announced key executive appointments including Graham Heap, MD, PhD as President of R&D, to advance Prifemilast into Phase 2 development for inflammatory bowel disease. The company also appointed heads of clinical development and medical affairs.

Clinical Trial Data

Phase

Phase 2

Importance:5/10

Sentiment:

0.60

managementleadershipexecutive appointmentsdrug developmentinflammatory bowel diseasePhase 2

Related Companies

$TAK

Read the original article

Published by PR Newswire Biotech on August 3, 2026 12:00 PM

Read Original

cAMPfield Strengthens Leadership Team with Key Executive Appointments, Including Graham Heap, MD, PhD as President, R&amp;D, to Advance Prifemilast into Global Phase 2 Development for Inflammatory Bowel Disease

Summary

Clinical Trial Data

cAMPfield Strengthens Leadership Team with Key Executive Appointments, Including Graham Heap, MD, PhD as President, R&D, to Advance Prifemilast into Global Phase 2 Development for Inflammatory Bowel Disease